Filgrastim-sndz
PreclinicalBiologic
Filgrastim-sndz is one of 10 biologic programs targeting Hematopoietic and Lymphoid System Neoplasm. It is currently in Preclinical.
1
Indications
8
Total Trials
2
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Hematopoietic and Lymphoid System Neoplasm
#DrugCompanyPhaseTrials
1Fludara
SanofiPreclinical
Cellcept
RochePreclinical
Rituxan
RochePreclinical
LUNSUMIO
RochePreclinical
Treanda
AAzurity Pharmaceuticals
Preclinical
Cytoxan
BBaxter Healthcare Corporation
Preclinical
Alkeran
AApotex Inc.
Preclinical
Prograf
VVeloxis Pharmaceuticals
Preclinical
Tafasitamab
IncytePreclinical
Filgrastim-sndz
MM.D. Anderson Cancer Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma2 trials
Acute Myeloid Leukemia2 trials
Leukemia2 trials
Acute Lymphoblastic Leukemia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Filgrastim-sndz. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- MM.D. Anderson Cancer Center